Latest filing published 30 May 2023 for Sangamo Therapeutics, INC, €2,170.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Rolf Andrew Ramelmeier: trading record in brief
This profile gathers the share dealings of Rolf Andrew Ramelmeier in Sangamo Therapeutics, Inc, where the filings describe the role as senior executive. Over a trading history stretching from 25 February 2020 to 25 May 2023, the count stands at 11 filings.
No open-market purchase appears, only 2 sales worth €83k. The rest of the record consists of 9 share grants.
On 30 May 2023 came the latest disclosure, a share grant for €2,170 in Sangamo Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Rolf Andrew Ramelmeier
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,750 shares@ US$1.333.2% of flowCommon StockSEC:0001209191-23-032912:0
- 45,000 shares0Common StockSEC:0001209191-23-016397:0
- 12,388 shares@ US$5.9096.8% of flowCommon StockSEC:0001209191-22-014173:0
3 of 3 declarations
